Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
| Author | |
|---|---|
| Abstract | :
Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. |
| Year of Publication | :
2017
|
| Journal | :
JAMA oncology
|
| Volume | :
3
|
| Issue | :
7
|
| Number of Pages | :
969-973
|
| Date Published | :
2017
|
| ISSN Number | :
2374-2437
|
| URL | :
https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.6007
|
| DOI | :
10.1001/jamaoncol.2016.6007
|
| Short Title | :
JAMA Oncol
|
| Download citation |